IT / EN
Close
IT / EN
Menu

Congenital Myopathies

Congenital myopathies are a heterogeneous group of hereditary muscle disorders characterized by hypotonia and muscle weakness present at birth or within the first months of life, defined by specific histological alterations of the muscle fiber. Despite the name, this group also includes certain clinical presentations of hereditary myopathies with onset during adolescence or adulthood. Unlike congenital muscular dystrophies, their course is typically non-progressive or only slowly progressive. The overall prevalence is estimated at 1:25,000 to 1:50,000 live births, and cognitive development is generally normal.

Congenital Myopathies: Genetics and Classification

Congenital myopathies are caused by mutations in various genes that encode structural muscle proteins. They are classified based on specific ultrastructural abnormalities observed under a microscope.

Classification by Histological Pattern

Each form presents specific diagnostic histological patterns:

  • Core Myopathies: Characterized by areas within the muscle fiber lacking oxidative enzyme activity (cores).

    • Primary genes: RYR1, SELENON (formerly SEPN1).

  • Nemaline Myopathies: Defined by the presence of small, rod-like structures called “nemaline bodies” in the muscle fibers.

    • Primary genes: NEB, ACTA1, TPM3.

  • Centronuclear Myopathies (CNM): Characterized by a high percentage of muscle fibers with nuclei located in the center rather than the periphery.

    • Primary genes: MTM1 (X-linked form), DNM2, BIN1.

  • Congenital Fiber Type Disproportion (CFTD): Diagnosed when Type 1 (slow-twitch) fibers are consistently and significantly smaller than Type 2 (fast-twitch) fibers.

Inheritance Patterns

The mode of inheritance is highly variable depending on the specific gene involved:

  • Autosomal Dominant

  • Autosomal Recessive

  • X-linked (notably the severe neonatal form of Myotubular Myopathy related to MTM1)

Ecco la traduzione professionale in inglese per la sintomatologia delle miopatie congenite:

Clinical Symptoms of Congenital Myopathies

While symptoms vary based on the specific subtype, they share several common clinical features:

Neonatal Presentation

  • Severe Hypotonia (“floppy baby syndrome”): Generalized weakness with reduced spontaneous movement.

  • Feeding Difficulties: Weak suckling and impaired swallowing (dysphagia).

  • Respiratory Failure: Often requiring ventilatory support from birth.

  • Characteristic Facies: Typical “myopathic” facial features (e.g., elongated face, “tented” upper lip).

  • Diminished or Absent Deep Tendon Reflexes.

Delayed Motor Development

  • Delayed Milestones: Head control achieved after 6 months; late attainment of independent sitting.

  • Ambulation: Delayed walking or inability to walk in severe forms.

  • Weakness Patterns: Primarily axial (trunk), proximal (shoulders and hips), facial, and respiratory.

Systemic Involvement

  • Respiratory: Early-onset respiratory insufficiency, recurrent lung infections, and chronic need for ventilation.

  • Skeletal: Progressive scoliosis, chest deformities (pectus excavatum/carinatum), joint contractures, and hip dysplasia.

  • Cardiac: Rare, though cardiomyopathy may occur occasionally in specific subtypes.

Subtype-Specific Characteristics

  • Central Core Disease (CCD): Strongly associated with a risk of Malignant Hyperthermia (a life-threatening reaction to certain anesthetics); motor function may show relative improvement with age.

  • Nemaline Myopathy: Highly variable, ranging from lethal neonatal forms to very mild, late-onset presentations.

  • X-linked Centronuclear Myopathy: Typically carries a guarded prognosis in males, while female carriers usually present with mild or no symptoms.

  • Diagnostic Evaluation of Congenital Myopathies

    The diagnostic process for congenital myopathies relies on a combination of clinical suspicion, specialized imaging, and advanced genetic analysis.

    • Neonatal Clinical Assessment: Identification of “red flags” such as hypotonia, a characteristic “frog-leg” posture, reduced spontaneous movements, and respiratory or feeding difficulties.

    • Laboratory Tests: Creatine Kinase (CK) levels are typically normal or only mildly elevated, reflecting the absence of active muscle fiber degeneration (unlike muscular dystrophies).

    • Muscle MRI: Used to identify subtype-specific patterns of muscle involvement and fatty replacement.

    • Genetic Diagnostics: A systematic approach using NGS (Next-Generation Sequencing) panels, histology-guided targeted analysis, and Whole Exome Sequencing (WES).

      Our center is equipped with advanced tools for the genomic and transcriptomic analysis of genes associated with these conditions.

    • Muscle Biopsy: Essential for highlighting specific pathognomonic alterations (such as central cores, nemaline bodies, or central nuclei) required for definitive diagnosis and classification.

    • Specialist Consultations:

      • Respiratory: Spirometry and arterial blood gas (ABG) analysis.

      • Cardiology: Echocardiogram.

      • Orthopedics: Monitoring for scoliosis and joint contractures.

Available therapies

Management and Treatment

Currently, there are no approved disease-modifying therapies; management is primarily symptomatic and supportive:

Respiratory Management

  • Early Ventilatory Support: Progressive use of non-invasive ventilation (NIV) such as CPAP/BiPAP, with invasive ventilation if necessary.

  • Airway Management: Respiratory physiotherapy, mechanical cough assistance (Cough Assist), and aggressive prevention of respiratory infections.

Nutritional Support

  • Swallowing Evaluation: Assessment via FEES (Fiberoptic Endoscopic Evaluation of Swallowing); use of temporary nasogastric tubes or PEG (Percutaneous Endoscopic Gastrostomy) in cases of severe dysphagia.

  • Metabolic Support: Vitamin supplementation and increased caloric intake to prevent malnutrition.

Multidisciplinary Rehabilitative Approach

  • Specialized Physiotherapy: Passive mobilization, motor stimulation, and neuromuscular facilitation.

  • Occupational Therapy: Development of fine motor skills, provision of daily living aids, and environmental adaptations.

  • Orthopedic Management: Prevention of skeletal deformities, use of orthoses (braces), and surgical intervention for scoliosis or severe joint contractures.

Experimental Therapies

  • Salbutamol: Investigated for specific forms such as centronuclear myopathies to improve muscle strength.

  • Gene Therapy: Development of AAV (Adeno-Associated Virus) vectors to deliver functional gene copies.

  • CRISPR Genome Editing: Research into precise genetic correction at the DNA level.

Research in progress

  • Research and Emerging Therapies

    The therapeutic landscape for congenital myopathies is expanding through several innovative research channels:

    • Experimental Drug Therapies: Clinical investigation of salbutamol, modafinil, and pyridostigmine to improve neuromuscular transmission and reduce fatigue.

    • Advanced Therapies: * Gene Therapies: Delivery of functional genes using viral vectors.

      • Genome Editing: Utilizing CRISPR-based technologies for mutation-specific corrections.

    • Biomarker Identification: Research focused on finding reliable biological markers to track disease progression and evaluate treatment outcomes.

    • Cellular Models: Development of patient-derived cell lines (such as iPSCs) for high-throughput drug screening and studying the underlying pathophysiology.

    • International Registries: Collaborative efforts to establish global patient databases to better characterize the natural history of these rare conditions.

    • Clinical Outcome Measures: Development and validation of disease-specific assessment scales to standardize how clinical outcomes are measured in trials.

Reference laboratory

Contacts and informations

Email/Telefono: malattieneuromuscolari@policlinico.mi.it / 02 5503 6504 Appointments CUP: 02 999 599 Sito web: www.centrodinoferrari.com

Associazioni pazienti: – UILDM: www.uildm.org – Tel. 049 8021001 – Congenital Myopathy International: organizzazione internazionale specifica – Cure CMD: risorse per miopatie congenite – A Foundation Building Strength: supporto famiglie miopatie congenite

Risorse specialistiche: – TREAT-NMD: www.treat-nmd.org – Network internazionale miopatie congenite – World Muscle Society: www.worldmusclesociety.org – Congenital Muscle Disease International Registry: database globale